acute pancreatitis
Conditions
Interventions
Experimental group:conventional treatment + parecoxib 40mg, iv, once a day for 3 days, and then imrecoxib, taken orally, 100mg each time, 2 times a day, for 27 days
Control group:conventional treatment + placebo B1, 1 injection each time, iv, once a day for 3 days, and then placebo B2, taken orally, 1 tablet each time, 2 times a day, for 27 days
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. consistent with the diagnosis of acute pancreatitis, having at least two of the following: (1) abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) serum amylase activity or lipase activity at least three times greater than the upper limit of normal; (3) characteristic findings of acute pancreatitis on computed tomography or magnetic resonance imaging or transabdominal ultrasonography; 2. either gender aged 18-75 years; 3. a score of APACHE II >=8; 4. no organ failure or transient organ failure lasting no more than 48 hours; 5. non-steroidal anti-inflammatory drugs and other similar drugs (e.g., glucocorticoids) were not used in the 2 weeks prior to the trial; 6. written informed consent was obtained from the patients or their legal representatives.
Exclusion criteria
Exclusion criteria: 1. drug allergy; 2. pregnancy and breast-feeding mother; 3. severe chronic diseases such as cardiac dysfunction, chronic obstructive pulmonary disease, renal insufficiency; as well as severe diseases in digestive system, including cirrhosis, esophageal varices, peptic ulcer, gastrointestinal bleeding in recent month, ulcerative colitis and Crohn's disease 4. drug abuse and psychosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of severe acute pancreatitis;The scores of organ failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| The scores of APACHE II;The scores of systemic inflammatory response syndrome (SIRS);The modified CT severity index;Local complications;Index of inflammation;The length of hospital stay;Hospital cost; | — |
Countries
China
Contacts
Public ContactChengwei Tang
West China Hospital, Sichuan University
Outcome results
None listed